Sawai Pharmaceutical has has struck a deal to take over eight facilities previously owned by scandal-hit Japanese pharmaceutical firm Kobayashi Kako. The two companies, as well as ORIX Corporation – which acquired a majority share in Kobayashi Kako in January 2020 – have agreed that Sawai will take over the company’s assets pertaining to production activities and the personnel of related divisions. Financial terms of the deal were not disclosed.
Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako
Japan’s Sawai Will Assume Ownership Of Eight Facilities Under New ‘Trust’ Subsidiary
Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.
More from Deals
• By
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?
• By
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
• By
Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.
• By
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
More from Business
• By
Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.
• By
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
• By
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.